Longer research reviews that connect many sources around one question.
Source-Backed Evidence Index / Browse Section
Deep Dives
Longer research reviews that connect many sources around one question.
Use this when you want the long version with grouped sources and careful limits.
A long source trail can still include uncertainty and mixed evidence.
Longer research reviews that connect many sources around one question.
Start with Minor cannabinoids safety surveillance map, CB1 receptor pharmacology research summary, CB2 receptor pharmacology research summary before moving into the full section index.
Deep reviews are long literature pages; use them to inspect evidence posture, uncertainty, and citation density together.
Start With Signal
Best first pages
Deep Review
Minor cannabinoids safety surveillance map
Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations?
36 evidence rows / 36 sources
Deep Review
CB1 receptor pharmacology research summary
What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1?
33 evidence rows / 33 sources
Deep Review
CB2 receptor pharmacology research summary
What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, selectivity, or structural pharmacology at CB2?
32 evidence rows / 32 sources
Deep Review
CB2 receptor immune/inflammation research summary
What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain-related mechanisms?
31 evidence rows / 31 sources
Deep Review
Cannabinoids and pregnancy/pediatrics heightened-review queue
Which cannabinoid evidence requires heightened review for pregnancy, pediatric, or developmental contexts?
30 evidence rows / 30 sources
Deep Review
CBD and seizure-related outcomes review
What evidence connects CBD with seizure-related outcomes or epilepsy-related clinical endpoints?
27 evidence rows / 27 sources
How To Read This Section
Use the page cards first. Open the source table when you want proof.
- Pick a page.Start with the title that matches your question.
- Read the plain summary.The top of each page explains the research in simple language.
- Check sources.Use PubMed and DOI links when you want to verify the details.
Complete Index
Full section index
| Page | Status | Evidence Rows | Sources |
|---|---|---|---|
| 2-AG research summary What evidence defines 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 14 | 14 |
| Acidic cannabinoid precursor research summary What evidence exists for acidic cannabinoid precursors such as CBGA, CBCA, THCVA, CBDVA, and CBNA? | source-backed draft | 12 | 12 |
| Anandamide research summary What evidence defines anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 15 | 15 |
| Cannabinoid product contamination and formulation risk review What evidence exists for contamination, labeling, formulation, or product-quality risks in cannabinoid products? | source-backed draft | 12 | 12 |
| Cannabinoids and cardiovascular risk heightened-review queue Which cannabinoid evidence requires heightened review for cardiovascular risk? | source-backed draft | 7 | 7 |
| Cannabinoids and cognition/memory research summary What evidence connects cannabinoids with cognition, memory, attention, or learning outcomes? | source-backed draft | 5 | 5 |
| Cannabinoids and immune modulation research summary What evidence connects cannabinoids with immune modulation or immune-system outcomes? | source-backed draft | 9 | 9 |
| Cannabinoids and liver enzyme/hepatotoxicity safety review What evidence connects cannabinoids with liver enzymes, hepatotoxicity, or hepatic safety monitoring? | source-backed draft | 12 | 12 |
| Cannabinoids and nausea/vomiting research summary What evidence connects cannabinoids with nausea, vomiting, emesis, or antiemetic outcomes? | source-backed draft | 7 | 7 |
| Cannabinoids and pregnancy/pediatrics heightened-review queue Which cannabinoid evidence requires heightened review for pregnancy, pediatric, or developmental contexts? | source-backed draft | 30 | 30 |
| Cannabinoids and psychiatric risk heightened-review queue Which cannabinoid evidence requires heightened review for psychiatric risk, psychosis, anxiety worsening, depression, or suicidality? | source-backed draft | 5 | 5 |
| Cannabinoids and sedation/somnolence safety review What evidence connects cannabinoids with sedation, somnolence, sleepiness, or next-day impairment? | source-backed draft | 6 | 6 |
| Cannabinoids and skin/dermatology research summary What evidence connects cannabinoids with skin, dermatology, or inflammatory skin outcomes? | source-backed draft | 13 | 13 |
| Cannabinoids dependence and withdrawal review What evidence connects cannabinoids with dependence, withdrawal, craving, or cannabis use disorder outcomes? | source-backed draft | 7 | 7 |
| CB1 and CB2 receptor pharmacology research summary What evidence defines cannabinoid activity at CB1 and CB2 receptors? | source-backed draft | 5 | 5 |
| CB1 receptor neurobehavioral/metabolic research summary What evidence connects CB1 receptor biology with neurobehavioral, reward, appetite, metabolic, pain, or cognition-related mechanisms? | source-backed draft | 24 | 24 |
| CB1 receptor pharmacology research summary What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, allostery, or structural pharmacology at CB1? | source-backed draft | 33 | 33 |
| CB2 receptor immune/inflammation research summary What evidence connects CB2 receptor biology with immune, inflammatory, microglial, neuroinflammatory, or pain-related mechanisms? | source-backed draft | 31 | 31 |
| CB2 receptor pharmacology research summary What evidence defines cannabinoid ligand binding, signaling, agonism, antagonism, selectivity, or structural pharmacology at CB2? | source-backed draft | 32 | 32 |
| CBC and inflammation-related outcomes research summary What evidence connects CBC with inflammation-related or pain-related outcomes? | source-backed draft | 9 | 9 |
| CBC and neurobehavioral/neurogenesis outcomes review What evidence connects CBC with neurobehavioral, mood, neural stem cell, or neurogenesis outcomes? | source-backed draft | 12 | 12 |
| CBC and pain-related outcomes research summary What evidence connects CBC with pain-related outcomes? | source-backed draft | 17 | 17 |
| CBC and safety/tolerability research summary What evidence connects CBC with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes? | source-backed draft | 21 | 21 |
| CBC and skin/dermatology research summary What evidence connects CBC with skin, dermatology, antimicrobial, or topical inflammatory outcomes? | source-backed draft | 21 | 21 |
| CBC and target/pharmacology research summary What evidence connects CBC with receptor, transporter, target, metabolic, or pharmacology mechanisms? | source-backed draft | 26 | 26 |
| CBD and anxiety-related outcomes review What evidence connects CBD with anxiety-related outcomes across human, animal, or mechanistic research? | source-backed draft | 10 | 10 |
| CBD and drug-interaction safety review What evidence connects CBD exposure with drug-interaction mechanisms or safety-relevant outcomes? | source-backed draft | 9 | 9 |
| CBD and pain-related outcomes research summary What evidence connects CBD with pain-related outcomes? | source-backed draft | 15 | 15 |
| CBD and seizure-related outcomes review What evidence connects CBD with seizure-related outcomes or epilepsy-related clinical endpoints? | source-backed draft | 27 | 27 |
| CBD and sleep-related outcomes review What evidence connects CBD with sleep-related outcomes? | source-backed draft | 12 | 12 |
| CBDA and nausea/inflammation research summary What evidence connects CBDA with nausea-related or inflammation-related outcomes? | source-backed draft | 25 | 25 |
| CBDV and seizure/neurodevelopmental outcomes review What evidence connects CBDV with seizure-related or neurodevelopmental outcomes? | source-backed draft | 21 | 21 |
| CBG and appetite/metabolic outcomes review What evidence connects CBG with appetite-related, weight, glucose, or metabolic outcomes? | source-backed draft | 16 | 16 |
| CBG and inflammation/immune outcomes research summary What evidence connects CBG with inflammation-related or immune outcomes? | source-backed draft | 22 | 22 |
| CBG and pain-related outcomes research summary What evidence connects CBG with pain-related outcomes? | source-backed draft | 11 | 11 |
| CBG and safety/tolerability research summary What evidence connects CBG with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes? | source-backed draft | 22 | 22 |
| CBG and skin/dermatology research summary What evidence connects CBG with skin, dermatology, or topical inflammatory outcomes? | source-backed draft | 14 | 14 |
| CBG and target/pharmacology research summary What evidence connects CBG with receptor, target, metabolic, or pharmacology mechanisms? | source-backed draft | 21 | 21 |
| CBN and pain-related outcomes research summary What evidence connects CBN with pain-related outcomes? | source-backed draft | 6 | 6 |
| CBN and safety/tolerability research summary What evidence connects CBN with safety, tolerability, sedation, adverse-event, or impairment outcomes? | source-backed draft | 9 | 9 |
| CBN and skin/inflammation research summary What evidence connects CBN with skin, dermatology, inflammatory, or immune-modulation outcomes? | source-backed draft | 9 | 9 |
| CBN and sleep pilot What evidence connects CBN with sleep-related outcomes? | source-backed draft | 23 | 10 |
| CBN and target/pharmacology research summary What evidence connects CBN with receptor, target, metabolic, or pharmacology mechanisms? | source-backed draft | 8 | 8 |
| Commercial and semi-synthetic cannabinoids safety review What safety evidence exists for Delta-8 THC, Delta-10 THC, HHC, and related commercial cannabinoid formulations? | source-backed draft | 12 | 12 |
| DHEA/synaptamide research summary What evidence defines DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 5 | 5 |
| Endocannabinoid enzyme research summary What evidence connects FAAH, MAGL, DAGL, NAPE-PLD, ABHD6, ABHD12, COX-2, LOX, and CYP enzymes with cannabinoid biology? | source-backed draft | 16 | 16 |
| Endocannabinoids and endocannabinoid-like lipids research summary What evidence defines endogenous cannabinoids and endocannabinoid-like lipids relevant to the encyclopedia? | source-backed draft | 13 | 13 |
| GPR119 cannabinoid target research summary What evidence connects cannabinoids, endocannabinoids, or endocannabinoid-like lipids with GPR119 activity, binding, signaling, or physiology? | source-backed draft | 8 | 8 |
| GPR18 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with GPR18 activity, binding, signaling, or physiology? | source-backed draft | 19 | 19 |
| GPR55 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with GPR55 activity, binding, signaling, or physiology? | source-backed draft | 18 | 18 |
| LEA research summary What evidence defines LEA biology, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 14 | 14 |
| Minor cannabinoids safety surveillance map Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations? | source-backed draft | 36 | 36 |
| NADA research summary What evidence defines NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 13 | 13 |
| Noladin ether research summary What evidence defines noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 12 | 12 |
| Non-canonical cannabinoid target research summary What evidence connects cannabinoids with PPARs, 5-HT1A, glycine receptors, adenosine signaling, opioid cross-talk, or dopamine/glutamate/GABA systems? | source-backed draft | 15 | 15 |
| OEA research summary What evidence defines OEA biology, receptor pharmacology, metabolism, feeding, metabolic physiology, or safety-relevant mechanisms? | source-backed draft | 14 | 14 |
| Oleamide research summary What evidence defines oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms? | source-backed draft | 13 | 13 |
| Orphan receptor cannabinoid targets research summary What evidence connects cannabinoids or endocannabinoids with GPR55, GPR18, and GPR119? | source-backed draft | 5 | 5 |
| PEA research summary What evidence defines PEA biology, receptor pharmacology, inflammation, pain-related mechanisms, metabolism, or safety-relevant mechanisms? | source-backed draft | 13 | 13 |
| Rare phytocannabinoids research summary What evidence exists for rare phytocannabinoids such as CBL, CBLA, CBT, CBCV, CBGV, and related acidic precursors? | source-backed draft | 7 | 7 |
| SEA research summary What evidence defines SEA biology, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 16 | 16 |
| THC and appetite/metabolic outcomes review What evidence connects THC or dronabinol with appetite, anorexia, weight, or metabolic outcomes? | source-backed draft | 10 | 10 |
| THC and cardiovascular-risk heightened-review queue What evidence connects THC exposure with cardiovascular outcomes or cardiovascular risk markers? | source-backed draft | 9 | 9 |
| THC and cognition/memory outcomes review What evidence connects THC exposure with cognition, memory, attention, learning, or acute impairment outcomes? | source-backed draft | 10 | 10 |
| THC and dependence/withdrawal review What evidence connects THC exposure with dependence, withdrawal, craving, or cannabis use disorder outcomes? | source-backed draft | 9 | 9 |
| THC and driving-impairment safety review What evidence connects THC exposure with driving impairment or other safety-relevant performance outcomes? | source-backed draft | 7 | 7 |
| THC and nausea/vomiting outcomes research summary What evidence connects THC or dronabinol with nausea, vomiting, emesis, or antiemetic outcomes? | source-backed draft | 8 | 8 |
| THC and pain-related outcomes research summary What evidence connects THC with pain-related outcomes? | source-backed draft | 9 | 9 |
| THC and psychiatric-risk heightened-review queue What evidence connects THC exposure with psychiatric risk, psychosis, anxiety worsening, depression, or suicidality? | source-backed draft | 9 | 9 |
| THC and sleep-related outcomes review What evidence connects THC with sleep-related outcomes? | source-backed draft | 10 | 10 |
| THCA and safety/effect claims review What evidence exists for THCA-specific safety, effect, or mechanism claims? | source-backed draft | 10 | 10 |
| THCV and appetite/metabolic outcomes review What evidence connects THCV with appetite-related or metabolic outcomes? | source-backed draft | 13 | 13 |
| THCV and inflammation/immune outcomes research summary What evidence connects THCV with inflammation-related or immune outcomes? | source-backed draft | 4 | 4 |
| THCV and neurobehavioral/cognition outcomes review What evidence connects THCV with neurobehavioral, cognition, mood, reward, or THC-interaction outcomes? | source-backed draft | 9 | 9 |
| THCV and pain-related outcomes research summary What evidence connects THCV with pain-related outcomes? | source-backed draft | 10 | 10 |
| THCV and safety/tolerability research summary What evidence connects THCV with safety, tolerability, adverse-event, impairment, or formulation-specific outcomes? | source-backed draft | 24 | 24 |
| THCV and target/pharmacology research summary What evidence connects THCV with receptor, target, metabolic, or pharmacology mechanisms? | source-backed draft | 23 | 23 |
| TRP channel cannabinoid target research summary What evidence connects cannabinoids with TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8? | source-backed draft | 11 | 11 |
| TRPA1 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with TRPA1 channel activity, binding, or signaling? | source-backed draft | 18 | 18 |
| TRPM8 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with TRPM8 channel activity, binding, or signaling? | source-backed draft | 15 | 15 |
| TRPV1 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with TRPV1 channel activity, desensitization, binding, or signaling? | source-backed draft | 18 | 18 |
| TRPV2 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with TRPV2 channel activity, binding, or signaling? | source-backed draft | 15 | 15 |
| TRPV3 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with TRPV3 channel activity, binding, or signaling? | source-backed draft | 12 | 12 |
| TRPV4 cannabinoid target research summary What evidence connects cannabinoids or endocannabinoids with TRPV4 channel activity, binding, or signaling? | source-backed draft | 14 | 14 |
| Virodhamine research summary What evidence defines virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms? | source-backed draft | 11 | 11 |